Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/97336
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPlummer, M.en
dc.contributor.authorChapman, M.en
dc.contributor.authorHorowitz, M.en
dc.contributor.authorDeane, A.en
dc.date.issued2014en
dc.identifier.citationCritical Care, 2014; 18(1):205-1-205-10en
dc.identifier.issn1364-8535en
dc.identifier.issn1466-609Xen
dc.identifier.urihttp://hdl.handle.net/2440/97336-
dc.description.abstractHyperglycaemia occurs frequently in the critically ill, even in those patients without a history of diabetes. The mechanisms underlying hyperglycaemia in this group are complex and incompletely defined. In health, the gastrointestinal tract is an important modulator of postprandial glycaemic excursions and both the rate of gastric emptying and the so-called incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, are pivotal determinants of postprandial glycaemia. Incretin-based therapies (that is, glucagon-like peptide- 1 agonists and dipeptidyl-peptidase-4 inhibitors) have recently been incorporated into standard algorithms for the management of hyperglycaemia in ambulant patients with type 2 diabetes and, inevitably, an increasing number of patients who were receiving these classes of drugs prior to their acute illness will present to ICUs. This paper summarises current knowledge of the incretin effect as well as the incretin-based therapies that are available for the management of type 2 diabetes, and provides suggestions for the potential relevance of these agents in the management of dysglycaemia in the critically ill, particularly to normalise elevated blood glucose levels.en
dc.description.statementofresponsibilityMark P Plummer, Marianne J Chapman, Michael Horowitz, and Adam M Deaneen
dc.language.isoenen
dc.publisherBioMed Centralen
dc.rights© 2014 BioMed Central Ltd.en
dc.subjectAnimals; Humans; Diabetes Mellitus, Type 2; Hyperglycemia; Blood Glucose; Glucagon-Like Peptide 1; Incretins; Dipeptidyl-Peptidase IV Inhibitorsen
dc.titleIncretins and the intensivist: what are they and what does an intensivist need to know about them?en
dc.typeJournal articleen
dc.identifier.rmid0030011339en
dc.identifier.doi10.1186/cc13737en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1025648en
dc.identifier.pubid107902-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS01en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidChapman, M. [0000-0003-0710-3283]en
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]en
dc.identifier.orcidDeane, A. [0000-0002-7620-5577]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.